Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etanercept response study in rheumatoid arthritis patients naive to TNF blockade or previously failing anti-TNF therapy
NL-OMON32681Phase 4Not yet recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Jan 2010
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of etanercept in rheumatoid arthritis (RA) (2 cohorts), sponsored by Amsterdam University Medical Center. Primary endpoints: Factors distinguishing responders from non-responders to etanercept and Response rate after 16 weeks of etanercept treatment. Planned start Jan 2010; status: not yet recruiting.
02
Drugs
etanercept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON32681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32681.